Gilda F. Linton
National Institutes of Health
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Gilda F. Linton.
Blood | 2010
Elizabeth M. Kang; Uimook Choi; Narda Theobald; Gilda F. Linton; Debra A. Long Priel; Doug B Kuhns; Harry L. Malech
Chronic granulomatous disease (CGD) is associated with significant morbidity and mortality from infection. The first CGD gene therapy trial resulted in only short-term marking of 0.01% to 0.1% of neutrophils. A recent study, using busulfan conditioning and an SFFV retrovirus vector, achieved more than 20% marking in 2 patients with X-linked CGD. However, oxidase correction per marked neutrophil was less than normal and not sustained. Despite this, patients clearly benefited in that severe infections resolved. As such, we initiated a gene therapy trial for X-CGD to treat severe infections unresponsive to conventional therapy. We treated 3 adult patients using busulfan conditioning and an MFGS retroviral vector encoding gp91(phox), achieving early marking of 26%, 5%, and 4% of neutrophils, respectively, with sustained long-term marking of 1.1% and 0.03% of neutrophils in 2 of the patients. Gene-marked neutrophils have sustained full correction of oxidase activity for 34 and 11 months, respectively, with full or partial resolution of infection in those 2 patients. Gene marking is polyclonal with no clonal dominance. We conclude that busulfan conditioning together with an MFGS vector is capable of achieving long-term correction of neutrophil oxidase function sufficient to provide benefit in management of severe infection. This study was registered at www.clinicaltrials.gov as #NCT00394316.
Stem Cells | 2004
Sebastian Brenner; Narda L. Whiting-Theobald; Toshinao Kawai; Gilda F. Linton; Andrew G. Rudikoff; Uimook Choi; Martin F. Ryser; Philip M. Murphy; Joan M.G. Sechler; Harry L. Malech
Hematopoietic stem cells (HSCs) lose marrow reconstitution potential during ex vivo culture. HSC migration to stromal cell–derived factor (SDF)‐1 (CXCL12) correlates with CXC chemokine receptor 4 (CXCR4) expression and marrow engraftment. We demonstrate that mobilized human CD34+ peripheral blood stem cells (CD34+ PBSCs) lose CXCR4 expression during prolonged culture. We transduced CD34+ PBSCs with retrovirus vector encoding human CXCR4 and achieved 18‐fold more CXCR4 expression in over 87% of CD34+ cells. CXCR4‐transduced cells yielded increased calcium flux and up to a 10‐fold increase in migration to SDF‐1. Six‐day cultured CXCR4‐transduced cells demonstrated significant engraftment in nonobese diabetic/severe combined immunodeficient mice under conditions in which control transduced cells resulted in low or no engraftment. We conclude that transduction‐mediated overexpression of CXCR4 significantly improves marrow engraftment of cultured PBSCs.
Blood | 2013
Randall K. Merling; Colin L. Sweeney; Uimook Choi; Suk See De Ravin; Timothy G. Myers; Francisco Otaizo-Carrasquero; Jason Pan; Gilda F. Linton; Lifeng Chen; Sherry Koontz; Narda Theobald; Harry L. Malech
A variety of somatic cells can be reprogrammed to induced pluripotent stem cells (iPSCs), but CD34(+) hematopoietic stem cells (HSCs) present in nonmobilized peripheral blood (PB) would be a convenient target. We report a method for deriving iPSC from PB HSCs using immunobead purification and 2- to 4-day culture to enrich CD34(+) HSCs to 80% ± 9%, followed by reprogramming with loxP-flanked polycistronic (human Oct4, Klf4, Sox2, and c-Myc) STEMCCA-loxP lentivector, or with Sendai vectors. Colonies arising with STEMCCA-loxP were invariably TRA-1-60(+), yielding 5.3 ± 2.8 iPSC colonies per 20 mL PB (n = 17), where most colonies had single-copy STEMCCA-loxP easily excised by transient Cre expression. Colonies arising with Sendai were variably reprogrammed (10%-80% TRA-1-60(+)), with variable yield (6 to >500 TRA-1-60(+) iPSC colonies per 10 mL blood; n = 6). Resultant iPSC clones expressed pluripotent cell markers and generated teratomas. Genomic methylation patterns of STEMCCA-loxP-reprogrammed clones closely matched embryonic stem cells. Furthermore, we showed that iPSCs are derived from the nonmobilized CD34(+) HSCs enriched from PB rather than from any lymphocyte or monocyte contaminants because they lack somatic rearrangements typical of T or B lymphocytes and because purified CD14(+) monocytes do not yield iPSC colonies under these reprogramming conditions.
Gene Therapy | 2007
Nora Naumann; S S De Ravin; Uimook Choi; Morvarid Moayeri; Narda L. Whiting-Theobald; Gilda F. Linton; Yasuhiro Ikeda; Harry L. Malech
X-linked chronic granulomatous disease (X-CGD) is a primary immunodeficiency caused by mutations in the phagocyte nicotinamide dinucleotide phosphate oxidase catalytic subunit gp91phox. Gene therapy targeting hematopoietic stem cells (HSCs) can correct CGD, but permanent correction remains a challenge. Lentiviral vectors have become attractive tools for gene transfer, and they may have the potential to transduce very primitive HSCs. We used a self-inactivating RD114/TR-pseudotyped simian immunodeficiency virus (SIVmac)-based vector encoding human gp91phox for ex vivo transduction of peripheral blood-mobilized stem cells (PBSCs) from patients with X-CGD. In PBSCs from two patients, ex vivo transduction efficiencies of 40.5 and 46% were achieved, and correction of oxidase activity was observed in myeloid cells differentiating in culture. When transduced PBSCs from these patients were transplanted into nonobese diabetic/severe combined immunodeficient mice and compared to normal control, 10.5 and 7.3% of the human myeloid cells in bone marrow developing at 6 weeks from the human xenografts expressed the gp91phox transgene. Sustained functional correction of oxidase activity was documented in myeloid cells differentiated from engrafted transduced PBSCs. Transgene marking was polyclonal as assessed by vector integration site analysis. These data suggest that RD114/TR SIVmac-based vectors might be suitable for gene therapy of CGD and other hereditary hematologic diseases.
Journal of Biological Chemistry | 2006
Ross M. Taylor; Danas Baniulis; James B. Burritt; Jeannie M. Gripentrog; Connie I. Lord; Marcia H. Riesselman; Walid S. Maaty; Brian Bothner; Thomas E. Angel; Edward A. Dratz; Gilda F. Linton; Harry L. Malech; Algirdas J. Jesaitis
The catalytic core of the phagocyte NADPH oxidase is a heterodimeric integral membrane protein (flavocytochrome b (Cyt b)) that generates superoxide and initiates a cascade of reactive oxygen species critical for the host inflammatory response. In order to facilitate structural characterization, the present study reports the first direct analysis of human phagocyte Cyt b by matrix-assisted laser desorption/ionization and nanoelectrospray mass spectrometry. Mass analysis of in-gel tryptic digest samples provided 73% total sequence coverage of the gp91phox subunit, including three of the six proposed transmembrane domains. Similar analysis of the p22phox subunit provided 72% total sequence coverage, including assignment of the hydrophobic N-terminal region and residues that are polymorphic in the human population. To initiate mass analysis of Cyt b post-translational modifications, the isolated gp91phox subunit was subject to sequential in-gel digestion with Flavobacterium meningosepticum peptide N-glycosidase F and trypsin, with matrix-assisted laser desorption/ionization and liquid chromatography-mass spectrometry/mass spectrometry used to demonstrate that Asn-132, -149, and -240 are genuinely modified by N-linked glycans in human neutrophils. Since the PLB-985 cell line represents an important model system for analysis of the NADPH oxidase, methods were developed for the purification of Cyt b from PLB-985 membrane fractions in order to confirm the appropriate modification of N-linked glycosylation sites on the recombinant gp91phox subunit. This study reports extensive sequence coverage of the integral membrane protein Cyt b by mass spectrometry and provides analytical methods that will be useful for evaluating posttranslational modifications involved in the regulation of superoxide production.
Stem Cells | 2007
Sebastian Brenner; Martin F. Ryser; Narda L. Whiting-Theobald; Marcus Gentsch; Gilda F. Linton; Harry L. Malech
We used the nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model to assess the repopulation potential of subpopulations of mobilized human CD34+ peripheral blood progenitor cells (PBPC). First, PBPC were transduced with γ‐retrovirus vector RD114‐MFGS‐CFP, which requires cell division for successful transduction, at 24 hours, 48 hours, and 72 hours to achieve 96% cyan fluorescent protein (CFP)‐positive cells. Cells were sorted 12 hours after the last transduction into CFP‐positive (divided cells) and CFP‐negative populations. CFP‐positive cells were transplanted postsort, whereas the CFP‐negative cells were retransduced and injected at 120 hours. The CFP‐negative sorted and retransduced cells contained markedly fewer vector copies and resulted in a 32‐fold higher overall engraftment and in a 13‐fold higher number of engrafted transgene positive cells. To assess cell proliferation as an underlying cause for the different engraftment levels, carboxyfluorescein succinimidyl ester‐labeling of untransduced PBPC was performed to track the number of cell divisions. At 72 hours after initiation of culture, when 95% of all cells have divided, PBPC were sorted into nondivided and divided fractions and transplanted into NOD/SCID mice. Nondivided cells demonstrated 45‐fold higher engraftment than divided cells. Late dividing PBPC in ex vivo culture retain high expression of the stem cell marker CD133, whereas rapidly proliferating cells lose CD133 in correlation to the number of cell divisions. Our studies demonstrate that late dividing progenitors transduced with γ‐retroviral vectors contribute most to NOD/SCID engraftment and transgene marking. Confining the γ‐retroviral transduction to CD133‐positive cells on days 3 and 4 could greatly reduce the number of transplanted vector copies, limiting the risk of leukemia from insertional mutagenesis.
Methods of Molecular Biology | 2007
Thomas L. Leto; Mark C. Lavigne; Neda Homoyounpour; Kristen Lekstrom; Gilda F. Linton; Harry L. Malech; Isabelle de Mendez
Polymorphonuclear neutrophils (PMN) have a remarkable capacity for generation of large amounts of reactive oxygen species in response to a variety of infectious or inflammatory stimuli, a process known as the respiratory burst that involves activation of a multicomponent NADPH oxidase. Given their short life span, PMN are not amenable to most molecular biology methods for studying activation of this oxidant-generating system. We have explored a variety of methods for introduction of components of the phagocytic oxidase (phox system) into the promyelocytic erythroleukemia cell line, K-562. Here, we describe a series of cloned K-562 cell lines that were retrovirally transduced for stable production of one or more essential components of the phagocytic oxidase (phox) complex. We outline methods for the use of these transfectable cells for investigating structure, function, and signaling requirements for assembly and activation of the phox system. These versatile lines can be used to examine effects of genetic polymorphisms or mutations in phox components associated with chronic granulomatous disease, to serve as a system for testing gene therapy vectors designed to correct the defective oxidase, to study cross-functioning with recently described phox component homologs, or to explore signaling components involved in regulation of the respiratory burst.
International Journal of Infectious Diseases | 2002
Gulbu Uzel; S.D. Rosenzweig; E. Tng; J.M. Shaw; M.E. Horwitz; Gilda F. Linton; S.M. Anderson; M.R. Kirby; J.I. Gallin; T.A. Fleisher; S.K.A. Law; Steven M. Holland
Reversion mutations in patients with leukocyte adhesion deficiency type I leading to CD18 expression on CD3+/CD8+/CD57+ T Cells G. Uzel,’ S. D. Rosenzweig2 E. Tng3 J. M. Shaw,j M. E. Horwitz,2 G. E Lintoq2 S. M. Anderson,4 M. R. Kirby,4 J. I. Galliq2 i? A. Fleisher,’ S. K. A. Law3 and S. M. Holland2 Clinical Center,’ DLM, Immunology Service, Laboratory of Host Defenseq2 NIAID; MRC Immunohistochemistry Unit3, Department of Biochemistry, University of Oxford, UK and 4NHGRI, NIH, Bethesda, MD 20892
Proceedings of the National Academy of Sciences of the United States of America | 1997
Harry L. Malech; Phillip B. Maples; Narda L. Whiting-Theobald; Gilda F. Linton; Sudhir Sekhsaria; Sarah J. Vowells; Fei Li; Judi A. Miller; Ellen S. DeCarlo; Steven M. Holland; Susan F. Leitman; Charles S. Carter; Robert E. Butz; Elizabeth J. Read; Thomas A. Fleisher; Richard D. Schneiderman; Dennis E. Van Epps; S. Kaye Spratt; Christopher A. Maack; Joseph Rokovich; Lawrence K. Cohen; John I. Gallin
Blood | 2007
Javier Chinen; Joie Davis; Suk See De Ravin; Beverly N. Hay; Amy P. Hsu; Gilda F. Linton; Nora Naumann; Effie Nomicos; Christopher Silvin; Jean Ulrick; Narda L. Whiting-Theobald; Harry L. Malech; Jennifer M. Puck